A Landmark Achievement in Australian Stem Cell Research

The Murdoch Children's Research Institute (MCRI) in Melbourne has achieved a groundbreaking milestone that could revolutionize treatments for blood disorders. After more than 25 years of global efforts, scientists at MCRI have successfully generated human hematopoietic stem cells (HSCs)—the master cells responsible for producing all blood components—from induced pluripotent stem cells (iPSCs). These lab-grown HSCs closely mimic those found in human embryos and have demonstrated transplantability in preclinical models, marking a world-first in functional equivalence.

This breakthrough stems from collaborative work involving key researchers Associate Professor Elizabeth Ng, Professor Andrew Elefanty, and Professor Ed Stanley, all affiliated with MCRI and the University of Melbourne's Department of Paediatrics. Their protocol addresses longstanding barriers in stem cell differentiation, offering hope for personalized bone marrow transplants without the need for donor matching.

HSCs, or hematopoietic stem cells, are rare cells residing primarily in bone marrow that self-renew and differentiate into red blood cells for oxygen transport, white blood cells for immunity, and platelets for clotting. Currently, patients with leukemia, aplastic anemia, or genetic blood diseases rely on donor transplants, facing risks like graft-versus-host disease due to mismatches. MCRI's innovation promises an off-the-shelf or patient-specific alternative, potentially transforming clinical practice.

The road to this discovery highlights Australia's strength in biomedical research. MCRI, embedded within the Royal Children's Hospital ecosystem, leverages proximity to clinical needs, fostering rapid translation from bench to bedside.

Decades of Dedication: The 25-Year Quest

Efforts to create functional human HSCs in the lab date back to the 1990s, with initial successes in mouse models. Human attempts faltered due to inefficient differentiation and poor engraftment—lab cells failed to establish long-term multilineage hematopoiesis in vivo. MCRI's team built on incremental advances, refining protocols over years.

Professor Elefanty and colleagues began exploring iPSCs—adult cells reprogrammed to an embryonic-like state by factors like Oct4, Sox2, Klf4, and c-Myc—in the mid-2000s. By mimicking embryonic development stages, they navigated mesoderm induction to hemogenic endothelium, the precursor to HSCs. This journey involved trial-and-error with growth factors, extracellular matrices, and culture conditions, underscoring the persistence required in academic research.

In Australian higher education, such long-term projects exemplify how university-affiliated institutes like MCRI sustain innovation through National Health and Medical Research Council (NHMRC) grants and partnerships. The persistence mirrors broader trends where Australian universities rank highly in clinical medicine, attracting talent and funding.

The Breakthrough Protocol: Step-by-Step Innovation

The MCRI method starts with patient-derived iPSCs formed into swirling embryoid bodies in a defined serum-free medium (SPELS). Key steps include:

• Mesoderm Induction: CHIR99021 (Wnt agonist), BMP4 (bone morphogenetic protein 4), and Activin A pattern posterior mesoderm expressing HOXA genes, crucial for blood formation sites.
• Hemogenic Endothelium Specification: High-dose VEGF (vascular endothelial growth factor) with BMP4, followed by timed VEGF withdrawal to trigger endothelial-to-hematopoietic transition (EHT).
• Retinoid Signaling: Retinyl acetate addition from day 3 enhances hemogenic potential, boosting transcriptional similarity to embryonic aortic-gonad-mesonephros (AGM) HSCs.
• Maturation: Cytokines like stem cell factor (SCF), thrombopoietin (TPO), and others support intra-aembryonic hematopoiesis mimicry.
• Harvest: CD34+ cells collected days 14-16, cryopreserved in DMSO, retaining viability.

This workflow yields pure, scalable HSCs suitable for banking, a leap from prior inefficient methods.

Proven Functionality: Engraftment in Preclinical Models

Validation came via transplantation into immunodeficient NSG-Kit W41/W41 mice modeling bone marrow failure. Two million thawed CD34+ cells from four iPSC lines engrafted multilineage in 25-50% recipients, achieving up to 70% human chimerism in bone marrow after 16 weeks—comparable to cord blood.

Engrafted cells formed a self-renewing compartment (CD34+ CD38lo/-), producing erythroid (GYPA+), myeloid (CD33+), B-lymphoid (CD19+), and T-lymphoid (CD3+) lineages. Secondary transplants showed limited serial potential, typical of early embryonic HSCs. Female mice engrafted better, and dose-response mirrored clinical standards.

Single-cell RNA sequencing confirmed maturity akin to embryonic HSCs. For details on the study, see the Nature Biotechnology publication.

Photo by DJ Paine on Unsplash

University of Melbourne and MCRI: Pillars of Collaboration

MCRI's success is intertwined with the University of Melbourne, where Ng, Elefanty, and Stanley hold professorial positions in Paediatrics. As part of reNEW—the Novo Nordisk Foundation Center for Stem Cell Medicine (Uni Melb, MCRI, WEHI)—this work exemplifies interdisciplinary hubs driving Australia's research prowess.

reNEW focuses on iPSC-derived therapies for heart, kidney, and blood diseases, training PhD students and postdocs. Peter MacCallum Cancer Centre and Monash University's Australian Regenerative Medicine Institute contributed, showcasing networked excellence.

Australian universities benefit from such ecosystems, with Melbourne ranking top in clinical sciences globally, fostering PhD programs and attracting NHMRC funding exceeding $100 million annually for stem cells.

Transforming Patient Care: From Lab to Clinic

For the 300+ Australian children awaiting bone marrow transplants yearly, this means reduced wait times (often 6-12 months), no mismatches, and gene-corrected cells for disorders like Fanconi anemia. Adults with myelodysplastic syndromes could access unlimited supplies.

Post-breakthrough, a $35 million Retro Biosciences partnership (2025) accelerates biomanufacturing. Phase I trials eyed in 5 years, pending funding. Globally, 100,000+ transplants occur annually; lab HSCs could universalize access.

Explore MCRI's ongoing work at their announcement.

Boosting Higher Education and Research Careers

This advance spotlights Australia's higher ed strengths, with Uni Melb's stem cell programs drawing international talent. reNEW offers PhD scholarships, postdoc fellowships, drawing 200+ researchers yearly.

Careers in regenerative medicine boom: demand for stem cell biologists up 30% per ARC data. Roles include iPSC engineering, CRISPR editing, biomanufacturing—salaries $120k-$180k for postdocs.

Universities like Melbourne host training via Master of Biomedical Science, preparing graduates for industry (CSL, Mesoblast) or academia. Check opportunities at research jobs.

Challenges and Ethical Horizons

Scalability, purity (99% needed clinically), and serial transplantation remain hurdles. Ethical iPSC use avoids embryo debates; regulatory paths via TGA mirror FDA's RMAT designation.

Australia's Therapeutic Goods Administration supports fast-tracking; NHMRC ethics ensure equity.

Photo by David Clarke on Unsplash

Future Prospects: Clinical Trials and Beyond

Next: Optimize for human trials, integrate CRISPR for gene therapy (e.g., sickle cell). reNEW targets heart/kidney too. By 2030, personalized HSCs could cut transplant mortality 50%.

Learn more about reNEW at their site.

This MCRI triumph cements Australia's leadership, inspiring higher ed innovation.